No Data
No Data
No Data
No Data
No Data
Express News | ARCA Biopharma Inc- Qtrly Net Loss 0.14 per Basic and Diluted Share
ReutersApr 25 16:56 ET
Express News | ARCA Biopharma Inc - G&a Expenses in 2024 Are Expected to Be Higher Than Those in 2023
ReutersApr 25 16:55 ET
Express News | ARCA Biopharma Inc - Expect to Continue to Incur Costs and Expenditures in Connection With Process of Evaluating Strategic Alternatives
ReutersApr 25 16:55 ET
Express News | ARCA Biopharma- Future Viability Beyond Middle of 2025 Is Dependent on Results of Strategic Review Process, Ability to Raise Additional Capital
ReutersApr 25 16:55 ET
Express News | ARCA Biopharma Inc - Cash and Cash Equivalents Will Be Sufficient to Fund Its Operations Through Middle of 2025
ReutersApr 25 16:54 ET
Express News | ARCA Biopharma Inc - Cash and Cash Equivalents Were $35.9 Mln as of March 31, 2024
ReutersApr 25 16:54 ET
No Data
No Data